問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiation Therapy

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Colorectal Surgery

Division of Others-

Division of Radiology

Digestive System Department

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-09-19

柳建安Liu, Chien-An
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • dorassistants@gmail.com

Recruiting Trial

100Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

柳建安

List

118Cases

2025-06-10 - 2033-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

  • Condition/Disease

    Colon Adenocarcinoma 、Rectal Adenocarcinoma

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2021-10-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-05-17 - 2030-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-02-07 - 2032-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-07-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-05-01 - 2031-08-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-06-16 - 2026-06-30

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma (ESCC)

  • Test Drug

    Keytruda injection RMK-4830MK-4280A Lenvima capsule R Lenvima capsule R Intaxel Injection R Irinotel Intravenous Infusion Concentrate

Participate Sites
7Sites

Recruiting7Sites

2021-01-01 - 2026-03-31

Phase III

Completed
A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    Pembrolizumab; Lenvatinib

Participate Sites
5Sites

Recruiting5Sites

2024-04-20 - 2031-02-28

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-01-10 - 2031-05-31

Phase II

Active
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers

  • Condition/Disease

    Gastrointestinal Cancer

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

1 3 4 5 6 7 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB